• NIFTY 11,596.90  (-0.78% )  
  • SENSEX 38,897.46  (-0.81%)  
  • USDINR 69.03  (0.16%)  
  • GOLD 34,990.00  (-0.28%)
  •  
  • Go
Corporate Information
Sun Pharma announces presentation of clinical data on ILUMYA (tildrakizumab-asmn)
(01 Mar 2019) Back
Sun Pharmaceutical Industries announced that one of its wholly owned subsidiaries presented new ILUMYA (tildrakizumab-asmn) clinical insights at the 2019 American Academy of Dermatology (AAD) Annual Meeting, including long-term data showing sustained skin clearance in some patients living with moderate-to-severe plaque psoriasis after three years of ongoing treatment with ILUMYA.